The global costs of schizophrenia.

The global costs of schizophrenia.

Schizophrenia is a chronic disease associated with a significant and long-lasting health, social, and financial burden, not only for patients but also for families, other caregivers, and the wider society. Many national and local studies have sought to estimate the societal burden of the illness--or...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	Knapp, M, Mangalore, R, Simon, J
Format:	Journal article
Sprog:	English
Udgivet:	2004

Lignende værker

The cost of schizophrenia in Japan
af: Sado M, et al.
Udgivet: (2013-05-01)

The global prevalence of schizophrenia.
af: Dinesh Bhugra
Udgivet: (2005-05-01)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
af: Correll Christoph U, et al.
Udgivet: (2008-04-01)

Costs and efficacy ofolanzapine and risperidone in schizophrenia
af: Vittorio Mapelli
Udgivet: (2007-06-01)

The cost of relapse and the predictors of relapse in the treatment of schizophrenia
af: Slade Eric P, et al.
Udgivet: (2010-01-01)

Cost of schizophrenia: direct costs and use of resources in the State of São Paulo
af: Leitão Raquel Jales, et al.
Udgivet: (2006-01-01)

Selective impairment of global motion integration, but not global form detection, in schizophrenia and bipolar affective disorder
af: Daniel Bennett, et al.
Udgivet: (2016-03-01)

Cost-effectiveness of Positive Memory Training (PoMeT) for the treatment of depression in schizophrenia
af: Simon, J, et al.
Udgivet: (2022)

Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia
af: Vos Theo, et al.
Udgivet: (2011-05-01)

The global fight against the stigma of schizophrenia.
af: Nadia Kadri, et al.
Udgivet: (2005-07-01)

The global fight against the stigma of schizophrenia.
Udgivet: (2005-07-01)

Local and global limits on visual processing in schizophrenia.
af: Marc S Tibber, et al.
Udgivet: (2015-01-01)

Cost-effectiveness of clozapine to prevent suicide in schizophrenia: Interim results
af: Dakin, H, et al.
Udgivet: (2003)

Correction: Local and Global Limits on Visual Processing in Schizophrenia.
af: Marc S Tibber, et al.
Udgivet: (2019-01-01)

Physical health examination in outpatients with schizophrenia: the cost effectiveness of laboratory screening tests
af: Saana Eskelinen, et al.
Udgivet: (2020-12-01)

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
af: Rui Luo, et al.
Udgivet: (2023-08-01)

A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
af: Ali Abdall-Razak, et al.
Udgivet: (2019-09-01)

Costs of Globalization
af: Farrukh Nawaz Kayani, et al.
Udgivet: (2012-12-01)

Cost/effectiveness of aripiprazole vs. olanzapine in the long-term treatment of schizophrenia
af: Dutina Aleksandra, et al.
Udgivet: (2019-01-01)

Global research in schizophrenia and serotonin: a bibliometric analysis
af: Gustavo Canul-Medina, et al.
Udgivet: (2024-08-01)

Correction: Local and global limits on visual processing in schizophrenia.
af: PLOS ONE Staff
Udgivet: (2015-01-01)

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
af: Faries Douglas E, et al.
Udgivet: (2010-01-01)

The cost-of-illness trend of schizophrenia in South Korea from 2006 to 2016.
af: Minkyung Jo, et al.
Udgivet: (2020-01-01)

Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis
af: Dan Chisholm, et al.
Udgivet: (2008-07-01)

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
af: Jia Liu, et al.
Udgivet: (2022-09-01)

Effects of medication adherence on hospitalizations and healthcare costs in patients with schizophrenia in Thailand
af: Piyameth Dilokthornsakul, et al.
Udgivet: (2016-03-01)

Olanzapine versus typical neuroleptics for schizophrenia: evaluation of social and economic costs
af: Giorgio Mariani, et al.
Udgivet: (2006-09-01)

Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder.
af: Dusan Hirjak, et al.
Udgivet: (2016-01-01)

Corrigendum: Global research in schizophrenia and serotonin: a bibliometric analysis
af: Gustavo Canul-Medina, et al.
Udgivet: (2024-09-01)

Global economic burden of schizophrenia: response to authors’ reply
af: Neil AL, et al.
Udgivet: (2017-02-01)

Functional graph alterations in schizophrenia: a result from a global anatomic decoupling?
af: Cabral, J, et al.
Udgivet: (2012)

Schizophrenia /
af: Hirsch, Steven R., et al.
Udgivet: (2003)

Still Regarding Schizophrenia, Secondary Schizophrenia, Pseudo-Schizophrenia, and Schizophrenia-Like Psychosis
af: João Gama Marques
Udgivet: (2022-06-01)

Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom
af: Amy Dymond, et al.
Udgivet: (2022-08-01)

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
af: Jia Liu, et al.
Udgivet: (2022-11-01)

Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria
af: Desislava Ignatova, et al.
Udgivet: (2019-01-01)

Costs of treating patients with schizophrenia who have illness-related crisis events
af: Peng Xiaomei, et al.
Udgivet: (2008-08-01)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
af: O&#39;Day K, et al.
Udgivet: (2013-09-01)

Schizophrenia in the Netherlands: Continuity of Care with Better Quality of Care for Less Medical Costs.
af: Arnold van der Lee, et al.
Udgivet: (2016-01-01)

Study Protocol: Global Research Initiative on the Neurophysiology of Schizophrenia (GRINS) project
af: Jun Wang, et al.
Udgivet: (2024-06-01)